Abstract
In 1993, the first disease-modifying therapy (DMT) specifically for relapsing-remitting multiple sclerosis (RRMS) was introduced, and an untreatable disease became treatable. The US Food and Drug Administration now has approved 14 DMTs in 8 classes with different mechanisms of action, administration routes, and side effects.1 This therapeutic palette allows neurologists to control RRMS in most patients.
Original language | English (US) |
---|---|
Pages (from-to) | 346-347 |
Number of pages | 2 |
Journal | Neurology |
Volume | 87 |
Issue number | 4 |
DOIs | |
State | Published - Jul 26 2016 |
ASJC Scopus subject areas
- Clinical Neurology